Guo Zhiye, Du Xiaolong, Zhang Yihua, Su Chunwan, Ran Feng, Lu Qiulun
Key Laboratory of Cardiovascular and Cerebrovascular Medicine, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, China.
Department of Vascular Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Front Cardiovasc Med. 2022 Jan 13;8:785554. doi: 10.3389/fcvm.2021.785554. eCollection 2021.
Chronic venous disease (CVD) is a progressive inflammatory disease that increases in prevalence with age. Elucidating the underlying molecular mechanism of CVD development is essential for disease prevention and treatment. This study constructed a mouse model of iliac vein stenosis to explore the mechanism of the CVD disease progression, and diosmin was administered as a positive control (as recommended by clinical practice). The mouse model was established successfully with iliac vein stenosis, leading to the expansion of the intercellular space and venous leakage. Conversely, micronized diosmin showed a dose-dependent therapeutic effect for these manifestations. Concerning the mechanism, iliac vein stenosis caused an inflammatory response in veins, while diosmin suppressed this increase. Furthermore, RNA sequencing analysis indicated that diosmin significantly improved muscle function through actin filament organization and muscle contraction. These results indicated that the mouse model of iliac vein stenosis is a reliable model to study venous diseases. Furthermore, the dose-dependent therapeutic effect of diosmin on stenosis (without toxic side-effects) suggests greater protection against venous diseases at higher doses of diosmin.
慢性静脉疾病（CVD）是一种进行性炎症性疾病，其患病率随年龄增长而增加。阐明CVD发生发展的潜在分子机制对于疾病的预防和治疗至关重要。本研究构建了髂静脉狭窄小鼠模型以探讨CVD疾病进展的机制，并给予地奥司明作为阳性对照（按照临床实践推荐）。成功建立了伴有髂静脉狭窄的小鼠模型，导致细胞间隙扩大和静脉渗漏。相反，微粉化地奥司明对这些表现具有剂量依赖性治疗作用。关于其机制，髂静脉狭窄引起静脉炎症反应，而地奥司明抑制了这种炎症反应增强。此外，RNA测序分析表明，地奥司明通过肌动蛋白丝组织和肌肉收缩显著改善了肌肉功能。这些结果表明，髂静脉狭窄小鼠模型是研究静脉疾病的可靠模型。此外，地奥司明对狭窄的剂量依赖性治疗作用（无毒性副作用）表明，更高剂量的地奥司明对静脉疾病具有更强的保护作用。
